Targeting on pyruvate dehydrogenase kinase 1 (PDK1) may help solve this dilemma since it could promote the glycolysis of EC cells exposed to long-term high-concentrated glucose; the combination of PDK1 inhibitor JX06 and metformin could inhibit EC cells growth in persistently hyperglycemic environment, which provides the therapeutic prospect for EC patients complicated with diabetes mellitus [146]. This evidence concerns the gene PDK1 and diabetes mellitus.